Targeting CD138−/CD20+ Clonogenic Myeloma Precursor Cells Decreases These Cells and Induces Transferable Antimyeloma Immunity-Reference-Cited by-同舟云学术

Targeting CD138−/CD20+ Clonogenic Myeloma Precursor Cells Decreases These Cells and Induces Transferable Antimyeloma Immunity

Published:2016-05 Issue:5 Volume:22 Page:869-878
ISSN:1083-8791
Container-title:Biology of Blood and Marrow Transplantation
language:en
Short-container-title:Biology of Blood and Marrow Transplantation

Author:

Lum Lawrence G.,Thakur Archana,Kondadasula Sri Vidya,Al-Kadhimi Zaid,Deol Abhinav,Tomaszewski Elyse N.,Yano Hiroshi,Schalk Dana L.,Ayash Lois,Zonder Jeffrey A.,Uberti Joseph P.,Abidi Muneer H.,Ratanatharathorn Voravit

Funder

Leukemia and Lymphoma Society

National Cancer Institute

Ray and Lynn Wood Neag Foundation

Young Family Foundation

Karmanos Cancer Institute

Publisher

Elsevier BV

Subject

Transplantation,Hematology

Reference36 articles.

1. High-dose intravenous melphalan for plasma-cell leukaemia and myeloma;McElwain;Lancet,1983

2. Multiple myeloma;Raab;Lancet,2009

3. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome;Attal;N Engl J Med,1996

4. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe;Fermand;J Clin Oncol,2005

5. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma;Child;N Engl J Med,2003

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting cancer stem cells in multiple myeloma;Trends in Cancer;2024-08

2. Looking ahead to CD3, T-cell engager bispecific antibodies for hematological malignancies;Expert Opinion on Biological Therapy;2024-07-29

3. Bispecific T cell engager-armed T cells targeting integrin ανβ6 exhibit enhanced T cell redirection and antitumor activity in cholangiocarcinoma;Biomedicine & Pharmacotherapy;2024-06

4. Targeting refractory/recurrent neuroblastoma and osteosarcoma with anti-CD3×anti-GD2 bispecific antibody armed T cells;Journal for ImmunoTherapy of Cancer;2024-03

5. Targeting GD2-positive Refractory/Resistant Neuroblastoma and Osteosarcoma with Anti- CD3 x Anti-GD2 Bispecific Antibody Armed T cells;2023-11-09